SHORT LEAD TIME, COMPETITIVE PRICE

PYRIDOSTIGMINE BROMIDE (CAS 101-26-8) is used to treat muscle weakness with myasthenia gravis or forms of congenital myasthenic syndrome. It prevents and combats the effects of drug toxicity (e.g. it is used by the US and Swiss armies).

THERAPEUTIC INDICATION: CENTRAL NERVOUS SYSTEM

PYRIDOSTIGMINE BROMIDE is used to treat muscle weakness with myasthenia gravis or forms of congenital myasthenic syndrome.

REGULATORY STATUS

GMP: EU, JP, US
US-DMF: YES
CEP: YES
EU-DMF: YES
COA: EP, USP

YOUR ADVANTAGES

Competitive price
Short lead time (stock product)
Batch size: approx. 1.100 kg

^{This article uses material from Wikipedia, which is released under the Creative Commons Attribution-Share-Alike License 3.0.}